Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800135 | 1.00 | KMT2A (0.42) | KMT2AFABP5FABP7DPP8DPP9 | |
| SCHEMBL3365554 | 1.00 | KMT2A (0.42) | KMT2AFABP5FABP7DPP8DPP9 | |
| SCHEMBL119635 | 0.84 | ACE (0.52) | FABP5FABP7 | |
| SCHEMBL29398714 | 0.84 | ACE (0.52) | FABP5FABP7 | |
| SCHEMBL13252698 | 0.84 | ACE (0.52) | FABP5FABP7 | |
| SCHEMBL119605 | 0.84 | ACE (0.52) | FABP5FABP7 | |
| SCHEMBL29400546 | 0.84 | ACE (0.52) | FABP5FABP7 | |
| SCHEMBL23723017 | 0.80 | FFAR1 (0.47) | KMT2AFABP5FABP7 | |
| SCHEMBL119493 | 0.80 | FFAR1 (0.47) | KMT2AFABP5FABP7 | |
| SCHEMBL20590863 | 0.80 | FFAR1 (0.47) | KMT2AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103447-A1 | METHODS FOR PREPARING PSMA CONJUGATES | ENDOCYTE, INC. | 2026-04-16 | — | — | US | disclosed |
| CN-120965522-B | Fmoc-Tea-OH, preparation method thereof and application thereof in polypeptide synthesis | 兰树化妆品股份有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-120965522-B | Fmoc-Tea-OH, preparation method thereof and application thereof in polypeptide synthesis | 兰树化妆品股份有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-120965522-A | Fmoc-Tea-OH, preparation method thereof and application thereof in polypeptide synthesis | 兰树化妆品股份有限公司 | 2025-11-18 | — | — | CN | disclosed |
| CN-120965522-A | Fmoc-Tea-OH, preparation method thereof and application thereof in polypeptide synthesis | 兰树化妆品股份有限公司 | 2025-11-18 | — | — | CN | disclosed |
| US-12473265-B2 | Methods for preparing PSMA conjugates | ENDOCYTE, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | disclosed |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-09-07 | — | — | US | disclosed |
| EP-4185336-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-05-31 | — | — | EP | disclosed |
| US-20220220085-A1 | METHODS FOR PREPARING PSMA CONJUGATES | ENDOCYTE, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103447-A1 | METHODS FOR PREPARING PSMA CONJUGATES | PSMA1, PSMA3, PSMA2 | KMT2A 2573/4885FABP5 484/4885FABP7 779/4885 |
| US-20220220085-A1 | METHODS FOR PREPARING PSMA CONJUGATES | FOLH1, PSMA6, PSMA1 | KMT2A 1594/4885FABP5 1264/4885FABP7 2152/4885 |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | KLK3, SHBG, SELPLG | KMT2A 2112/4885FABP5 1433/4885FABP7 1744/4885 |
| US-12473265-B2 | Methods for preparing PSMA conjugates | FOLH1, PSMA6, PSMA1 | KMT2A 1594/4885FABP5 1264/4885FABP7 2152/4885 |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SPINT2, SERPINB1 | KMT2A 4666/4885FABP5 1206/4885FABP7 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.